Johnson & Johnson negotiating to buy biotech company Centocor
This article was originally published in Clinica
Executive Summary
Johnson & Johnson is believed to be in talks to acquire the US biotech firm, Centocor, in a share deal valued at more than $3 billion. Shares in Centocor, which have already risen sharply in recent weeks on takeover rumours, climbed a further $1.75 to $48.63 on May 4. Both companies declined to comment on the potential acquisition.